Cargando…
Imatinib Resistance in Chronic Myeloid Leukemia Associated with a D363G BCR::ABL1 Kinase Domain Mutation
Acquired resistance to tyrosine kinase inhibitors (TKIs) remains a therapeutic challenge in the treatment of chronic myeloid leukemia (CML). The most studied reason for TKI resistance is the acquisition of mutations within the BCR::ABL1 tyrosine kinase domain (KDM) and of which the majority of which...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139808/ https://www.ncbi.nlm.nih.gov/pubmed/37123466 http://dx.doi.org/10.1155/2023/6673144 |
_version_ | 1785033025762885632 |
---|---|
author | Langabeer, Stephen E. Macleod, Stuart Bhreathnach, Úna Fadalla, Kamal |
author_facet | Langabeer, Stephen E. Macleod, Stuart Bhreathnach, Úna Fadalla, Kamal |
author_sort | Langabeer, Stephen E. |
collection | PubMed |
description | Acquired resistance to tyrosine kinase inhibitors (TKIs) remains a therapeutic challenge in the treatment of chronic myeloid leukemia (CML). The most studied reason for TKI resistance is the acquisition of mutations within the BCR::ABL1 tyrosine kinase domain (KDM) and of which the majority of which occur at seven codons within this region. A case of CML is described in which presence of a rare D363G BCR::ABL1 KDM resulted in a suboptimal response to frontline imatinib. Switching to dasatinib resulted in achieving a sustained major molecular response that was maintained after a subsequent switch to bosutinib due to the side effects. Reporting of such cases is important for the future management of any CML patients with this rare mutation. |
format | Online Article Text |
id | pubmed-10139808 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-101398082023-04-28 Imatinib Resistance in Chronic Myeloid Leukemia Associated with a D363G BCR::ABL1 Kinase Domain Mutation Langabeer, Stephen E. Macleod, Stuart Bhreathnach, Úna Fadalla, Kamal Case Rep Hematol Case Report Acquired resistance to tyrosine kinase inhibitors (TKIs) remains a therapeutic challenge in the treatment of chronic myeloid leukemia (CML). The most studied reason for TKI resistance is the acquisition of mutations within the BCR::ABL1 tyrosine kinase domain (KDM) and of which the majority of which occur at seven codons within this region. A case of CML is described in which presence of a rare D363G BCR::ABL1 KDM resulted in a suboptimal response to frontline imatinib. Switching to dasatinib resulted in achieving a sustained major molecular response that was maintained after a subsequent switch to bosutinib due to the side effects. Reporting of such cases is important for the future management of any CML patients with this rare mutation. Hindawi 2023-04-20 /pmc/articles/PMC10139808/ /pubmed/37123466 http://dx.doi.org/10.1155/2023/6673144 Text en Copyright © 2023 Stephen E. Langabeer et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Langabeer, Stephen E. Macleod, Stuart Bhreathnach, Úna Fadalla, Kamal Imatinib Resistance in Chronic Myeloid Leukemia Associated with a D363G BCR::ABL1 Kinase Domain Mutation |
title | Imatinib Resistance in Chronic Myeloid Leukemia Associated with a D363G BCR::ABL1 Kinase Domain Mutation |
title_full | Imatinib Resistance in Chronic Myeloid Leukemia Associated with a D363G BCR::ABL1 Kinase Domain Mutation |
title_fullStr | Imatinib Resistance in Chronic Myeloid Leukemia Associated with a D363G BCR::ABL1 Kinase Domain Mutation |
title_full_unstemmed | Imatinib Resistance in Chronic Myeloid Leukemia Associated with a D363G BCR::ABL1 Kinase Domain Mutation |
title_short | Imatinib Resistance in Chronic Myeloid Leukemia Associated with a D363G BCR::ABL1 Kinase Domain Mutation |
title_sort | imatinib resistance in chronic myeloid leukemia associated with a d363g bcr::abl1 kinase domain mutation |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139808/ https://www.ncbi.nlm.nih.gov/pubmed/37123466 http://dx.doi.org/10.1155/2023/6673144 |
work_keys_str_mv | AT langabeerstephene imatinibresistanceinchronicmyeloidleukemiaassociatedwithad363gbcrabl1kinasedomainmutation AT macleodstuart imatinibresistanceinchronicmyeloidleukemiaassociatedwithad363gbcrabl1kinasedomainmutation AT bhreathnachuna imatinibresistanceinchronicmyeloidleukemiaassociatedwithad363gbcrabl1kinasedomainmutation AT fadallakamal imatinibresistanceinchronicmyeloidleukemiaassociatedwithad363gbcrabl1kinasedomainmutation |